Circadin® launch rollout starts with the launch of the product in the important German market

 

"We are very happy to have launched Circadin® in Germany, which is the first of the 15 markets in Europe where Lundbeck expects to roll out Circadin® during 2008," says Executive Vice President Stig Løkke Pedersen, Head of Commercial Operations. He continues: "Circadin® is the first sleep agent to be launched in Europe since 1999, and with a new mechanism of action that mimics the physiological profile of the body's own melatonin secretion, Circadin® will be a highly valuable alternative to traditional sedative hypnotics, which share a number of drawbacks such as dependency and residual drowsiness."

 

Circadin® is the first and only IP-protected, prolonged-release, melatonin-containing prescription drug approved in the EU. Melatonin is a naturally occurring hormone produced by the pineal gland; and it has a pivotal role in the regulation of circadian rhythms and sleep. Endogenous melatonin levels decrease with age and may contribute to the common complaint of poor sleep quality seen amongst those in middle age and in the elderly. Administration of Circadin®, which essentially mimics the normal nocturnal melatonin profile, improves sleep quality and morning alertness and facilitates sleep onset in patients aged 55 or over.

 

The content of this release will have no influence on the Lundbeck Group's financial result for 2008.

 

 

Lundbeck contacts

 

Investors:	Media:
Jacob Tolstrup	Jens Højbjerg
Director	Media Relations Manager
+45 36 43 30 79	+45 36 43 28 33
Palle Holm Olesen
Head of Investor Relations
+45 36 43 24 26

 

Stock Exchange Release No 341 - 13 May 2008

 

H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2007, the company's revenue was DKK 11 billion (approximately EUR 1.5 billion or USD 2.0 billion). The number of employees is approximately 5,300 globally. For further information, please visit www.lundbeck.com